Cancer Pain is a multidimensional pain experience which involves diverse neurophysiological changes and is associated with significant cognitive, emotional and sociocultural problems. Globally, the incidence is very high and usually it is undertreated Lack of knowledge about managing malignant pain is an important cause of undertreatment. All types of pain are possible with malignancies. Assessment of pain characteristics is vital for proper management. The WHO step ladder pattern is the cornerstone of management. There are different pharmacological and nonpharmacological methods. Morphine is the choice opioid being administered by various routes. All drugs should be used as round the clock regimen. Opioid switch is opted to tackle tolerance. Nerve blockade especially with alcohol are still being used today. Newer treatment modalities like implantable intrathecal pumps, dorsal column stimulation are in the pipeline for future. A passionate counselling may frequently release knotted conundrum of difficult analgesic strategies.
2. Chwistek M. Recent advances in understanding and managing cancer pain. F1000Res. 2017;6:945.
3. Doyle KE, El Nakib SK, Rajagopal MR, Babu S, Joshi G, Kumarasamy V et al. Predictors and prevalence of pain and its management in four regional cancer hospitals in India. J Glob Oncol. 2018;4:1-9.
4. Portenoy RK. Treatment of cancer pain. Lancet. 2011;377:2236-47.
5. Kumar KH, Elavarasi P. Definition of pain and classification of pain disorders. J Adv Clin Res Insights. 2016;3:87-90.
6. Stewart J. The challenges of cancer pain assessment. Ulster Med J. 2014;83:44-6.
7. Sharma KS. Development of specialist palliative care in indian cancer care setting: A personal journey of three decades. Indian J Palliat Care. 2016;22:237-8.
8. Carlson CL. Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. J Pain Res. 2016; 9:515-34.
9. Sun V, Borneman T, Piper B, Koczywas M, Ferrell B. Barriers to pain assessment and management in cancer survivorship. J Cancer Surviv. 2008;2:65-71.
10. Meghani SH, Knafl GJ. Patterns of analgesic adherence predict health care utilization among outpatients with cancer pain. Patient Prefer Adherence. 2016;10:81-98.
11. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain:
recommendations of the task group of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–8.
12. Ripamonti CI, Bandieri E, Roila F; ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 Suppl 6:vi69-77.
13. Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014 ;32:1677-90.
14. Nair A S, Ubale P. Flupirtine: A narrative review of its role in acute and chronic pain management. Med One. 2017; 2: e170006.
15. Carmona-Bayonas A, Jiménez Fonseca P, Virizuela Echaburu J. Tapentadol for cancer pain management: A narrative review. Pain Pract. 2017;17:1075-88.
16. Sawhney M, Fletcher GG, Rice J, Watt-Watson J, Rawn T. Guidelines on management of pain in cancer and/or palliative care. Toronto (ON): Cancer Care Ontario; 2017(22). Program in Evidence-Based Care Evidence Summary No.:18-4.
17. Mercadante S, Bruera E. Opioid switching in cancer pain: From the beginning to nowadays. Crit Rev Oncol Hematol. 2016;99:241-8.
18. Heo MH, Kim JY, Hwang I, Ha E, Park KU. Analgesic effect of quetiapine in a mouse model of cancer-induced bone pain. Korean J Intern Med. 2017;32:1069-74.
19. Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol. 2013;75:60-78.
20. YVonne D’arcy. Using mixed agonist-antagonists. Nursing 2019;35(2):17.
21. Kumar PP. Role of radiotherapy in management of cancer pain. J Natl Med Assoc. 1979;71:279-81.
22. Klepstad P, Kurita GP, Mercadante S, Sjøgren P. Evidence of peripheral nerve blocks for cancer-related pain: a systematic review. Minerva Anestesiol. 2015;81:789-93.
23. Smith TJ, Saiki CB. Cancer pain management. Mayo Clin Proc. 2015;90:1428-39.
24. Hasuo H, Ishihara T, Kanbara K, Fukunaga M. Myofacial trigger points in advanced cancer patients. Indian J Palliat Care. 2016;22:80-4.
25. Chambers WA. Nerve blocks in palliative care. Br J Anaesth. 2008;101:95-100.
26. Jan J. Rykowski, Maciej Hilgier; Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: influence on pain relief. Anesthesiology2000;92(2):347.
27. Bethann M. Scarborough; Cardinale B. Smith. Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin 2018;68:182–96.
28. Bolash R, Udeh B, Saweris Y, Guirguis M, Dalton JE, Makarova N et al. Longevity and cost of implantable intrathecal drug delivery systems for chronic pain management: a retrospective analysis of 365 patients. Neuromodulation. 2014;18:150-5.
29. Majithia N, Smith TJ, Coyne PJ, Abdi S, Pachman DR, Lachance D et al. Scrambler therapy for the management of chronic pain. Support Care Cancer. 2016;24:2807-14.